

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Dean L. Engelhardt et al.

Serial No.

08/479,997

Group Art Unit: 1656

Filed:

June 7, 1995

Examiner: Scott W. Houtteman

Title: OLIGO- OR POLYNUCLEOTIDES, AND

OTHER COMPOSITIONS COMPRISING PHOSPHATE MOIETY LABELED

NUCLEOTIDES

TRANSMITTAL SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§1.56 & 1.97-1.98

HON. COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

Sir:

Transmitted herewith is an Information Disclosure Statement which is being filed in accordance with 37 C.F.R. §§ 1.56 and 1.97-1.98. The items listed on Form PTO-1449, a copy of which is enclosed, may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

- 1. [] For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:
- 2. [] For each of the following items listed on the enclosed copy of form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
- 3. [] Any copy of the items on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in the prior [] Divisional or [] Continuation-In-Part application under 37 C.F.R. §1.60, U.S. Serial No.
- 4. [] No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:

03/19/2001 FFRNAEIA 00000009 051135 08479997 01 FC:126 180.00 CH

Enz-5(D6)(C2)

#39 1)9) 3/2/0/

- [] 37 C.F.R. ∋1.97(b)(1), within three months of the filing date of the above-identified application.
- [] 37 C.F.R. ∋1.97(b)(2), within three months of the date of entry into the national stage as set forth in ∋1.491 in an international application.
- [] 37 C.F.R. ∍1.97(b)(3), before the mailing date of a first Office action on the merits.
- 5. [] No fee is due under 37 C.F.R. ∋1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. ∋1.97(e) set forth in paragraph 9 below.
- 6. [x] A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):
 - [] A check in the amount of \$240.00 is enclosed in payment of the fee.
 - [x] Charge the fee to Deposit Account No. 05-1135, Order No. ENZ-5(D6)(C2)). A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- 7. [] A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:
 - a. one of the certification pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
 - the attached petition requesting consideration of this Information Disclosure Statement; and
 - c. the fee due under 37 C.F.R. §1.17(i)(1) which is paid as set forth in paragraph 10 below.
- 8. [] A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with:
 - a. [] 37 C.F.R. §1.313(b)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue;
 - b. [] 37 C.F.R. §1.313(b)(5), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue.
 - c. [] The fee due under 37 C.F.R §1.17(i)(1) is paid as set forth in paragraph 10 below.

- 9. [] I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- [] I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in ∍1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- 10. [] A check in the amount of \$130.00 is enclosed in payment of the fee due under 37 C.F.R. §1.17(i)(1).
 - [] Charge the fee under 37 C.F.R. §1.17(i)(1) to Deposit Account No. 05-1135.
 Order No. ______ A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
 - [x] The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 05-1135. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

Dated: March 15, 2001

RONALD C. FEDUS Registration No. 32,567

Mailing Address:

ENZO DIAGNOSTICS, INC. c/o Enzo Biochem, Inc. 527 Madison Avenue, 9th Floor New York, New York 10022 Telephone: (212) 583-0100 Telefax: (212) 583-0150



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

> 527 Madison Avenue, 9th Floor New York, New York 10022 March 15, 2001

FILED VIA EXPRESS MAIL

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§1.56 & 1.97-1.98

Dear Sirs:

Pursuant to the provisions of 37 C.F.R. §§ 1.97-1.98, and in full compliance with their duty of disclosure under 37 C.F.R. §1.56, Applicants, through their attorney, are bringing the following twenty-two (22) documents to the attention of the U.S. Patent and Trademark Office and the Examiner handling their above-identified application:

- Organic Chemistry of Nucleic Acids, Part B, Kochetkov, N.K. and Budovskii, E.I., Editors, Chapter 9, pages 449-477, Plenum Press, London and New York (1972) [Exhibit 1];
- Armstrong, V. W. and Eckstein, F., "Interaction of substrate analogues with Escherichia coli DNA-dependent RNA polymerase," <u>Eur. J. Biochem</u> 70:33-38 (1976) [Exhibit 2];

"Express Mail" Label No.:

"Express Mail" Label No.:

Deposit Date:

I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.110 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C./20231

Ronald C. Fedus
Reg. No. 32,567

- 3. Rozovskaya, T.A. et al., "Introduction of a fluorescent label at the 3'-OH end of DNA and the 3'-OH end of the growing RNA chain," Molkulyarnaya Biologiya 11(3):598-610 (l977)[Exhibit 3]';
- Petrov, A. I. And Sukhorukov, B.I., "Spin-labeled polyribonucleotides," <u>Nucleic Acids Research 8(18)</u>:4221-4234 (1980) [Exhibit 4];
- Hiratsuka, T. and Uchida, K., "Preparation and Properties of 2'(or 3')-O-(2,4,6-trinitrophenyl) Adenosine 5'-Triphosphate, An Analog of Adenosine Triphosphate," <u>Biochimica et Biophysica Acta 320</u>:635-647 (1973) [Exhibit 5];
- Kourilsky, P. et al., GB-2,019,408 [Exhibit 6];
- Bauman J.G.J. et al., "Rapid and high resolution detection of in situ hybridisation to polytene chromosomes using fluorochrome-labeled RNA," <u>Chromosoma (Berl.)</u> 84:1-18 (I981) [Exhibit 7];
- 8. Bauman J.G.G. et al., "Cytochemical hybridization with hybridization with fluorochrome-labeled RNA," <u>J. Histochem. Cytochem 29</u>:227-237 (I981) [Exhibit 8];
- Broker T.R. et al., "Electron microscopic visualization fo tRNA genes with ferritin-avidin biotin labels," <u>Nucleic Acids Research 5(2)</u>:363-384 (I978) [Exhibit 9];
- Sodja A. and Davidson, N., "Gene mapping and gene enrichment by the avidin-biotin interaction: use of cytochrome-c as a polyamine bridge," <u>Nucleic Acids Research 5(2)</u>:385-401 (1978) [Exhibit 10];
- Daniel F.B. and Behrman, "Osmium (VI) Complexes of the 3',5'-Dinucleoside Monophosphates, ApU and UpA," <u>Biochemistry</u> 15(3):565-568 (I976) [Exhibit 11];
- 12. Ward D.C. et al., European Patent EP 0 063 879 [Exhibit 12];
- Eberhard W. et al., "Galactopyranosyl-B(1-3')-ribonucleosides-structural evidence and synthesis," <u>Nucleic Acids Research 9</u>:15-19 (I981) [Exhibit 13];
- Saffhill R. and Hall, J.J., "A Convenient Preparatin Of Isomerically Pure Nucleoside 5'-Monophosphates From Unprotected Nucleosides," <u>Carbohydrates Nucleosides Nucleotides 8</u>:573-583 (l981) [Exhibit 14];
- 15. Scherberg N.H., U.S. Patent No. 4,260,737 [Exhibit 15];
- 16. Kourilsky, P., German Patent DE 29 15 082 [Exhibit 16];
- Halloran, M.J. et al., "The Preparation Of Nucleotide-Protein Conjugates: Carbodiimides As Coupling Agents," <u>J. Immunology 96</u>:373-378 (I966) [Exhibit 17];
- Erlanger B.F. and Beiser, S.M., "Antibodies Specific For Ribonucleosides And Ribonucleotides And Their Reaction With DNA," <u>Proc. Natl. Acad. Sci.</u> <u>52</u>:68-74 (I964); [Exhibit 18];
- 19. Suzuki S. et al., "The Binding Sites of Nucleosides or Nucleotides To

Diethylenetriaminiecobalt (III)," <u>Bioinorganic Chemistry 3</u>:281-293 (I974). [Exhibit 19];

- Jeng et al., "The Use Of Aryl Azido ATP Analogs As PhotoAffinity Labels For Myosin ATPase," <u>J. Supramolecular Structure 3</u>:448-468 (1975) [Exhibit 20];
- 21. Gottikh et al., "The General Synthetic Route To Amino Acid Esters Of Nucleotides And Nucleosides-5'-Triphosphates And Some Properties Of These Compounds," <u>Tetrahedron 26</u>:4419-4433 (I970) [Exhibit 21];
- 22. <u>Biochemistry, Third Edition</u>, Stryer, L., Editor, pages 96-97 W.H. Freeman and Co., New York (1988);

The above-referenced twenty-two (22) references [Exhibits 1-22] were cited in a European opposition proceedings involving European patent, No. EP 0 286 898 B1, granted on a divisional application with claims to a different invention from those pending in the present application.

Eight (8) exhibits, namely Exhibits 2, 6-7, 9, 12, and 15-17 were previously cited or made of record in this application in some form, and are therefore not being included on accompanying Form PTO-1449. Specifically, Exhibit 2 was cited in the Declaration of Dean L. Engelhardt In Support Of Adequate Description and Enablement submitted as an Exhibit to An Amendment Under 37 CFR 1.116 filed 11/24/97. Exhibit 9 was cited in the Declaration of Dr. Ann Sodja in support of Applicants' January 18, 2001 Amendment Under 37 CFR 1.116. The remaining exhibits previously made of record in this application, namely, Exhibits 6-7, 12, 15 and 17 were cited in either an Information Disclosure Statement or a Supplemental Information Disclosure Statement submitted in connection with this pending application. Kourilsky et al, GB 2019,408 (Exhibit 6), was previously cited in the October 4, 1994 Office Action issued in the immediate parent application, serial no. 08/046,004, filed April 9, 1993. Applicants addressed this document both in their September 18 1995 Second Preliminary Amendment (pages 14-16) and in their September 20, 1995 Supplemental Amendment to Applicants' September 18, 1995 Second Preliminary Amendment. Exhibit 16, Kourilsky et al, German Patent DE 29 15 082, is related to the above-discussed Kourilsky Great Britian Patent, No. 2 019,408 (Exhibit 6) by virtue of sharing the same priority information.

A completed Form PTO-1449 listing the accompanying remaining fourteen (14) Exhibits, namely, Exhibits 1, 3-5, 8, 10-11, 13-14, and 18-22 is also attached hereto as Exhibit 23.

By this voluntary citation of art, Applicants and their attorney are requesting that the

Enz-5(D6)(C2)

documents be made of record in the instant application.

The above citation of references is not a representation that these documents constitute a complete or exhaustive listing, nor that the above listing necessarily includes the closest or most relevant references, nor are these documents necessarily a complete listing of all references known to Applicants or their attorney. It is simply a voluntary citation of references made in good faith, which is not intended to serve in any way as a substitute for the Examiner's own search.

In view of the general and specific features described and claimed in the present application, Applicants respectfully submit that the present invention is neither suggested nor disclosed by the documents referred to above and is thus patentably distinct thereover.

Applicants do not believe, and do not submit, by the citation of these references, that these references, either by themselves or in combination with other references, render the invention prima facie obvious under the new duty of disclosure rules.

Applicants respectfully request that the Examiner make the above-submitted documents of record in the instant application. Applicants further request that the Examiner consider these documents as any of them may relate to the instant application.

The fee under 37 C.F.R. §1.17(p) for filing this Information Disclosure Statement is \$180.000. The Patent and Trademark Office is hereby authorized to charge the amount of this fee (and any other fees in connection with this IDS) to Deposit Account No. 05-1135, or to credit any overpayment thereto.

Respectfully submitted.

Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

ENZO DIAGNOSTICS, INC. c/o Enzo Biochem, Inc. 527 Madison Avenue, 9th Floor New York, New York 10022 Tel. (212) 583-0100

Form PTO-1449 U.S. Department of Commerce	Atty. Docket No. ENZ-5(D6)(C2)	Serial No. 08/479.997
(REV. 8-83) Patent and Trademark Office	2112 0(33)(32)	
INFORMATION DISCLOSURE CITATION O 1 P (use several sheets if necessary)		
() () ()	Applicants: Dean L. Enge	elhardt et al.
MAR 1 5 2001	Filed: June 5, 1995	Group: 1656

EXAMINER'S COPY

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DO	сим	ENT	NUM	IBER	· 		DATE	NAME	CLAS	SU SS CL	B ASS	FILING DATE IF APPRO- PRIATE
		1		İ										
								_						
										 				
			<u> </u>			ļ								
	Ì													
	-													
				_	<u>.</u>					<u> </u>		_		
										-		-		
	\dashv												_	
	<u>. </u>												NJ	MAI
	ł												НЭJ	% ()
										 			<u>55</u>	· M
												1 ;) } 	MAR 2 2 2001
								_				2	\$	_ III

FOREIGN PATENT DOCUMENTS

DOG	ENT	NUM	BER	,		DATE	COUNTRY	CLASS	SUB CLASS	TRAN LATIC YES	N N
				_			ļ	ļ			
					!						
							<u> </u>				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED
	Hiratsuka, T. and Uchida, K., <u>Biochimica et Biophysica Acta</u> 320:635-647 (I973)
	Petrov, A. I. And Sukhorukov, B.I., Nucleic Acids Research 8(18):4221-4234 (1980)
	Rozovskaya, T.A. et al., Molkulyamaya Biologiya 11(3):598-610 (1977)
	Organic Chemistry of Nucleic Acids, Part B., Kochetkov, N.K. and Budovskii, E.i., Editors, Chapter 9, pages 449-477, Plenum Press, London & NY (1972)

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce	Atty. Docket No. ENZ-5(D6)(C2)	Serial No. 08/479,997
(REV. 8-83) Patent and Trademark Office		
O 1 P & (use several sheets if necessary)	·	
() () () () () () () () () ()	Applicants: Dean L. Enge	elhardt et. al.
MAR 1 5 2001	Filed: June 5, 1995	Group: 1656
TAADEWINE S	Filed: June 5, 1995	Group: 1656

U.S. PATENT DOCUMENTS

	DO	сим	ENT	NUM	BER		DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPRO- PRIATE
										775	
										CH/C	
							 			17	PE
						-				10 K	2)
							 		1 3	201	*
							 ·		8	3	TT TT
\dashv							 			() ——
		DO	DOCUM	DOCUMENT						DOCOMENT NOMBER DATE NAME	DOCUMENT NUMBER DATE NAME CLASS CLASS

FOREIGN PATENT DOCUMENTS

DO	CUM	ENT	NUM	BER		DATE	COUNTRY	CLASS	SUB CLASS	TRAN LATIC YES	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED
	Eberhard, W. et al., Nucleic Acids Research 9:15-19 (1981)
	Daniel F.B. and Behrman, <u>Biochemistry 15(3)</u> :565-568 (I976)
	Sodja, A. and Davidson, N., <u>Nucleic Acids Research 5(2)</u> :385-401 (I978)
	Bauman, J.G.G., <u>J. Histochem. Cytochem 29</u> :227-237 (1981)

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1	U.S. D	epart	tment	t of C	omm	ierce	ı		Docket No. Z-5(D6)(C2)		Serial No. 08/479,997				
(REV. 8-83) Pa	itent and	d Trac	dema	irk O	ffice				(- / /	}					
INFORM							N								
OIPE (us	e severa	il Sire	ets n	neu	385aı	у)		Appli	icants: Dean L. E	ngelhard	t et. al.		*		
唐 15 2000 A	i														
MAR 1 5 2001								Filed	: June 5, 1995		Group:	165	6		
PADEMARKS							<u> </u>			L_					
	-1					_ ს.ა	. PA	TENT DOCU	MENTS	- T				ING	
EXAMINER			2								s	:UB	DA.	TE IF	
INITIAL	DOC	CUME	ENT I	NUM	BER		т-	DATE	NAME	CLA		LASS		ATE	
													\perp		
													<u>L</u>		
							Γ_			-					
	T_{\perp}			•											
													+		
													1		
			\neg										 		
													_		
•	' '	,													
						•	l	I	ŀ	ı	1		1		
					F(OREI	GN F	PATENT DO	CUMENTS	!					
					FC	OREI	GN F	ATENT DO	CUMENTS	<u> </u>	<u>.</u>		TRAN	 IS-	
	DO	CUM	ENT	NUM			GN F	PATENT DO		21.400	SUB		LATIC	<u>NC</u>	
	DO	CUMI	ENT	NUM			GN F		COUNTRY	CLASS					
	DO	CUM	ENT	NUM			GNF			CLASS			LATIC YES CO	NO NO	
	DO	CUM	ENT	NUM			GN F			CLASS			LATIC YES CONCENTY	NO NO	
	DO	CUM	ENT	NUM			GN F			CLASS			LATIC YES CO	NC NC	
	DO	CUM	ENT	NUM			GN F			CLASS			LATIC YES CONCENTY	NO NO	
					1BER			DATE	COUNTRY		CLA		LATIC YES CONCENTY	NO NO	
	01	THER	DOC	CUMI	1BER	S (Inc	ludin	DATE	COUNTRY	It Pages.	CLA CLA	.ss	LATIC YES CONCENTY	N N	
	OT Saffi	THER	DOC	CUMI Hall,	BER ENTS J.J.,	S (Inc	bludin	DATE g Author, Tit	COUNTRY le, Date, Pertinen psides Nucleotide	t Pages, s 8:573-6	CLA CLA	.ss	LATIC YES CONCENTY	N N	
	O1 Saffil	THER hill R.	DOC and	CUMI Hall,	MBER ENTS J.J.,	S (Inc Carb	Sludin Dohyd M., Pr	DATE g Author, Tit lrates Nucleo	le, Date, Pertinenosides Nucleotide	t Pages, s 8:573-6	CLA CLA	.ss	LATIC YES CONCENTY	N N	
	O1 Safff Erlar Suzu	THER hill R. nger E	and B.F. a	CUMI Hall, and B	ENTS J.J., Beiser	S (Inc Carb r, S.M	lludin pohyd M., Pr	DATE g Author, Tit lrates Nucleo oc.Natl.Acao nistry 3:281-	le, Date, Pertinen osides Nucleotide d.Sci. 52:68-74 (IS	t Pages, s 8:573-6	CLA CLA	.ss	LATIC YES CONCENTY	N N	
	OI Saffil Erlar Suzu Jeng	THER hill R. nger Euki S. g et al	B.F. a et al.	CUMI Hall, and E	ENTS J.J., Beiser	S (Inco	Sludinoohyd	g Author, Tit Irates Nucleo oc.Natl.Acao nistry 3:281-	country le, Date, Pertinen osides Nucleotide d.Sci. 52:68-74 (IS 293 (I974) 468 (I975)	t Pages, s 8:573-6	CLA CLA	.ss	LATIC YES CONCENTY	N N	
	O1 Safff Erlar Suzu Jeng Gotti	THER hill R. nger E uki S. g et al	et al., J. &	CUMI Hall, and E	ENTS J.J., Beiser pinorg	S (Inc Carb r, S.M anic ecula	cher Cher	g Author, Tit Irates Nucleo oc. Natl. Acad mistry 3:281- icture 3:448- 9-4433 (1970)	COUNTRY le, Date, Pertinent posides Nucleotide 1.Sci. 52:68-74 (IS 293 (I974) 468 (I975)	t Pages, s 8:573-	Etc.) 583 (198	81)	ATIC YES	N NO	
	O1 Safff Erlar Suzu Jeng Gotti	THER hill R. nger E uki S. g et al ikh et	et al., J. &	CUMI Hall, and E	ENTS J.J., Beiser pinorg	S (Inc Carb r, S.M anic ecula	cher Cher	g Author, Tit Irates Nucleo oc. Natl. Acad mistry 3:281- icture 3:448- 9-4433 (1970)	country le, Date, Pertinen osides Nucleotide d.Sci. 52:68-74 (IS 293 (I974) 468 (I975)	t Pages, s 8:573-	Etc.) 583 (198	81)	ATIC YES	ON NO	
	O1 Safff Erlar Suzu Jeng Gotti	THER hill R. nger E uki S. g et al ikh et	et al., J. &	CUMI Hall, and E	ENTS J.J., Beiser pinorg	S (Inc Carb r, S.M anic ecula	cher Cher	g Author, Tit Irates Nucleo oc.Natl.Acad mistry 3:281- icture 3:448- 9-4433 (1970)	le, Date, Pertinen osides Nucleotide (1.5ci. 52:68-74 (15:293 (1974) 468 (1975))	t Pages, s 8:573-	Etc.) 583 (198	81)	ATIC YES	N N N N N N N N N N N N N N N N N N N	
EXAMINER: Init	O1 Saffi Erlar Suzu Jeng Gotti Bioci (1988	THER hill R. nger E uki S. g et al ikh et chemis	et al., J. Set al.	CUMI Hall, and E	ENTS J.J., Beiser pinorg	S (Inc Carb r, S.M panic ecula on, S	Cher ::4419	g Author, Tit Irates Nucleo oc. Natl. Acad nistry 3:281- icture 3:448- 9-4433 (1970) L., Editor, p	country le, Date, Pertinen esides Nucleotide d.Sci. 52:68-74 (IS 293 (I974) 468 (I975) bages 96-97, W.H	t Pages, s 8:573-	Etc.) 583 (I98	B1)	LATIC YES		

Form PTO-1449 U.S. Department of Commerce